#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating patients with mental health conditions need this evidence to avoid recommending cannabis based on insufficient data, as most psychiatric indications lack robust clinical trial support despite patient demand. This gap between patient expectations and available evidence creates an opportunity for clinicians to redirect resources toward evidence-based treatments while identifying which mental health conditions might warrant further cannabis research. The finding underscores the importance of informed consent conversations where clinicians acknowledge cannabis’s unproven status for most psychiatric disorders rather than offering it as a validated therapeutic option.
A recent systematic review examining cannabis use for psychiatric and mental health conditions found insufficient evidence to support its efficacy for most disorders, including anxiety, depression, and post-traumatic stress disorder, with the exception of some limited data supporting cannabinoid use for chemotherapy-induced nausea. The analysis highlights a critical gap between widespread patient interest and clinical cannabis use for mental health and the actual quality of evidence available to guide prescribing decisions. Current evidence limitations are particularly problematic given that many patients turn to cannabis seeking alternatives to conventional psychotropic medications or as adjunctive treatments. For clinicians, this underscores the importance of maintaining evidence-based skepticism about cannabis recommendations for psychiatric conditions and the need for transparent conversations with patients about the lack of robust clinical data. Practitioners should continue relying on established pharmacological and psychotherapeutic interventions as first-line treatments while documenting patient interest in cannabis and participating in further research efforts. The key practical takeaway is that clinicians should avoid endorsing cannabis for mental health conditions based on anecdotal reports alone and instead counsel patients that rigorous research is still needed before cannabis can be recommended as an evidence-based psychiatric treatment.
“After two decades, I can tell you that cannabis rarely belongs in a first-line treatment algorithm for depression or anxiety, and the patients who benefit most are those with specific, refractory conditions like PTSD or treatment-resistant epilepsy where we’ve exhausted conventional options. What frustrates me is that people come in expecting cannabis to solve their mental health crisis when what they actually need is therapy, sleep hygiene, or a properly optimized antidepressant, and my job is to be honest about that even though it’s not what they want to hear.”
🧠 While cannabis is increasingly used by patients reporting mental health symptoms, this study’s conclusion that evidence is limited for most psychiatric conditions reflects a genuine gap between clinical practice and rigorous evidence. The heterogeneity of cannabis products, dosing regimens, cannabinoid ratios, and delivery methods—combined with small sample sizes and methodological challenges in existing research—makes it difficult to draw firm conclusions about efficacy for depression, anxiety, PTSD, or other common conditions. Clinicians should recognize that patient self-reports of benefit do not establish causation, and that cannabis use carries documented risks including dependence, cognitive effects, and potential symptom exacerbation in vulnerable populations. The acknowledgment that certain refractory conditions with few alternatives may warrant further investigation is reasonable, but this should not lower the threshold for evidence in routine practice. Given the current evidence landscape, practitioners should maintain high standards for documentation, screen for contraindications and drug interactions
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: